

Supplemental Material

Supplemental Table 1: Demographic, prediction and outcome variables in cohort 1 and 2, indicating any statistically significant differences between the cohorts and the factors associated with seizures in cohort 2. GCS: Glasgow Coma Score, HIV: Human immunodeficiency virus, HSV: herpes simplex virus. Denominator given when missing data.

| | | Cohort 1 (n=203) | Cohort 2 (n=233) | Cohort 1 vs Cohort 2 p value | Cohort 2 Seizures (n=84) | Cohort 2 No seizures or not recorded (n=149) | Cohort 2 Seizure vs no seizure p value |
|-----------------------------|-------------------|-----------------------------|-----------------------------|---|---|---|---|
| Age, years, median (IQR) | | 31 (9-55) | 54 (34-68) | p < 0.001 | 53 (31-67) | 55 (36-69) | p = 0.155 |
| Sex, n (%) | Male | 109 (54) | 118 (51) | p = 0.525 | 41 (49) | 77 (52) | p = 0.685 |
| Aetiology, n (%) | HSV | 38 (19) | 65 (28) | p = 0.069 | 29 (35) | 36 (24) | p = 0.002 |
| | Autoimmune | 42 (21) | 39 (17) | | 22 (26) | 17 (11) | |
| | Unknown | 75 (37) | 89 (38) | | 23 (27) | 66 (44) | |
| | Infection (other) | 48 (24) | 40 (17) | | 10 (12) | 30 (20) | |
| Ethnicity, n (%) | White | 148 (73) | 210 (91) | p < 0.001 | 76 (91) | 134 (91) | p = 0.419 |
| | Black | 26 (13) | 8 (3) | | 2 (2) | 6 (4) | |
| | Asian | 21 (10) | 10 (4) | | 3 (4) | 7 (5) | |
| | Mixed | 5 (3) | 2 (1) | | 2 (2) | 0 (0) | |
| | Other | 55 (27) | 22 (9) | | 1 (1) | 1 (1) | |
| HIV, n (%) | Yes | 18 (9) | 9 (4) | p = 0.056 | 4 (5) | 5 (4) | p = 0.725 |
| GCS categories, n/total | ≤8 | 29/149 | 25/227 | p = 0.012 | 17/81 | 8/146 | p < 0.001 |
| | 9-12 | 30/149 | 38/227 | | 19/81 | 19/146 | |
| | 13-14 | 40/149 | 95/227 | | 29/81 | 66/146 | |
| | 15 | 50/149 | 69/227 | | 16/81 | 53/146 | |
| Symptoms | Fever | 158 (78) | 102 (44) | p < 0.001 | 37 (44) | 65 (44) | p = 1.000 |
| | Seizure | 121 (60) | 84 (36) | p < 0.001 | - | - | - |


Supplementary table 2: Development of provisional scoring system for seizure risk in encephalitis using binary logistic regression model based upon pooled estimates from imputed data in derivation cohort (cohort 1). AUROC: area under the receivers operating curve, HSV: Herpes Simplex Virus

| Seizure risk – Provisional model | | | | |
|---|--------------------------|----------------|--------------------------------|---|
| Variable | Model OR (95% CI) | p-value | Regression co-efficient | Risk Score |
| GCS | | | | |
| 0 | 1.00 | - | 0 | 0 |
| Per point | 0.73 (0.63-0.84) | <0.001 | -0.318 | 1 / one point reduction (Maximum 12) |
| Aetiology | | | | |
| Antibody-associated | 11.99 (2.09-68.86) | 0.017 | 2.484 | 8 |
| HSV | 3.58 (1.06-12.12) | 0.096 | 1.274 | 4 |
| Unknown | 1.90 (0.67-5.37) | 0.085 | 0.641 | 2 |
| Infection (other) | 1.39 (0.47-4.13) | 0.071 | 0.328 | 1 |
| Immune (other) | 1.00 | - | | 0 |
| Model performance | | | | Total Score 0-20 |
| AUROC Derivation cohort | 0.775 [0.701-0.848] | <0.001 | | |
| AUROC Validation cohort | 0.744 [0.677-0.811] | <0.001 | | |

Supplementary Table 3: Calibration: Expected/observed proportions for provisional seizure risk score in original data, imputed datasets and validation data.

| Observed | | Predicted | | E | O | E/O |
|--------------------------------|------------|------------|---------|-------|-------|-------|
| | | No Seizure | Seizure | | | |
| Original data | No seizure | 44 | 20 | 0.537 | 0.570 | 0.941 |
| | Seizure | 25 | 60 | | | |
| Imputation 1 | No seizure | 59 | 23 | 0.542 | 0.596 | 0.909 |
| | Seizure | 34 | 87 | | | |
| Imputation 2 | No seizure | 59 | 23 | 0.557 | 0.596 | 0.934 |
| | Seizure | 31 | 90 | | | |
| Imputation 3 | No seizure | 57 | 25 | 0.532 | 0.596 | 0.893 |
| | Seizure | 38 | 83 | | | |
| Imputation 4 | No seizure | 50 | 32 | 0.606 | 0.596 | 1.017 |
| | Seizure | 30 | 91 | | | |
| Imputation 5 | No seizure | 49 | 33 | 0.616 | 0.596 | 1.033 |
| | Seizure | 29 | 92 | | | |
| Pooled | No seizure | 54.8 | 32.4 | 0.596 | 0.570 | 1.045 |
| | Seizure | 27.2 | 88.6 | | | |
| External validation (cohort 2) | No seizure | 73 | 73 | 0.621 | 0.357 | 1.741 |
| | Seizure | 13 | 68 | | | |

Supplemental Figure 1: Linear calibration plot for provisional seizure model in validation cohort (cohort 2).



Regression equations

1) Preliminary model

$$\text{Log}(p/1-p) = 3.523 + 2.484 * \text{Aet}(\text{Antibody}) + 1.274 * \text{Aet}(\text{HSV}) + 0.641 * \text{Aet}(\text{Unk}) + 0.328 * \text{Aet}(\text{Inf}) - 0.318 * \text{GCS}$$

2) SEIZURE score

$$\text{Log}(p/1-p) = 0.024 + 0.862 * \text{Age}(<5) + 0.141 * \text{Age}(5-18) + 1.068 * \text{Age}(18-40) + 0.775 * \text{Age}(40-60) + 0.736 * \text{Fever} + 3.113 * \text{Aet}(\text{Antibody}) + 2.305 * \text{Aet}(\text{Bacterial}) + 1.731 * \text{Aet}(\text{Unknown}) + 1.711 * \text{Aet}(\text{Infother}) + 1.540 * \text{Aet}(\text{HSV}) + 1.005 * \text{Aet}(\text{ADEMimm}) + 0.728 * \text{Aet}(\text{MTB}) - 0.237 * \text{GCS}$$

3) For reference only: Admission SEIZURE score (without aetiology in model)

$$\text{Log}(p/1-p) = 2.048 + 0.601 * \text{Age}(<5) + 0.173 * \text{Age}(5-18) + 0.877 * \text{Age}(18-40) + 0.650 * \text{Age}(40-60) + 0.466 * \text{Fever} - 0.244 * \text{GCS}$$